Effect of edaravone on serum CRP in patients with cerebral infarction after thrombolytic therapy
10.3760/cma.j.issn.1008-6706.2011.16.006
- VernacularTitle:依达拉奉对脑梗死患者尿激酶溶栓后血清C-反应蛋白的影响
- Author:
Ziyuan LIU
- Publication Type:Journal Article
- Keywords:
Acute cerebral infarction;
Urokinase;
C-reactive protein;
Edaravone
- From:
Chinese Journal of Primary Medicine and Pharmacy
2011;18(16):2172-2173
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the therapeutic effect and the level of C-reactive protein of Edaravone on acute cerebral infarction after thrombolytic therapy in urokinase,and to discuss edaravone on brain tissue protective effect of thrombolytic. Methods41 patients with cerebral infarction were,divided into 2 groups randomly:treatment group(19cases) and control group(22 cases). Control group received thrombolytic therapy,and treatment group was treated with Edaravone at a dose of 30mg,twice a day,for 14 days. Clinical outcomes and neurological deficit score were evaluated before and after treatment. At the same time, serum CRP levels in patients were determend by immune turbidimetry. ResultsThe treatment group whose neurological deficit score better than the control group ( P ＜ 0.05),the total effective rate was significantly higher( P ＜ 0.01 ) ,compared with the control group, the treatment group CRP levels were significantly lower ( P ＜ 0. 05 ). ConclusionEdaravone on acute cerebral infarction in patients after thrombolysis can significantly improve the clinical efficacy, reduce serum CRP levels, recovery and prognosis of cerebral infarction is important, Edaravone can significantly improve neurological function in patients with acute cerebral infarction,protects against cerebral ischemia after thrombolysis in metabolic poisons further damage.
